ILCs in MM progression. (A) Gating strategy for ILC identification and transcription factor expression in different ILC subsets present in BM and PB. (B) The plot represents the percentages of ILCs (Lin^–/CD127⁺) expressed as median values ± SEM in PB and BM of patients with MM among the different stages (MGUS, SMM, and NDMM). (C) Representative Sunburst view of the ILC subsets among leukocytes (CD45⁺ cells, dark orange circle). Lin^–CD127⁺ cells (orange circle), ILC1 (light orange), ILC2 (green), and ILC3 (light green) among the different MM stages in PB (left) and BM (right), analyzed with Cytobank Premium. (D-F) Frequency of ILC1 (D), ILC2 (E), and ILC2 CRTH2⁺CD117^– (F) in PB and BM of patients with MM among the different stages. A Mann-Whitney t test was performed; ∗P < .05 and ∗∗P < .005.